Moss S E, Klein R, Klein B E
Department of Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Madison, USA.
Ophthalmology. 1998 Jun;105(6):998-1003. doi: 10.1016/S0161-6420(98)96025-0.
The purpose of the study was to estimate the 14-year incidence of visual loss in a diabetic population and to examine its relationship to potential risk factors.
Cohort study.
A population-based sample of younger onset diabetic persons diagnosed younger than 30 years of age and taking insulin (n = 880) were examined at baseline, 4 years, 10 years, and 14 years.
Visual acuity (VA) as measured by the Early Treatment Diabetic Retinopathy Study protocol was performed.
Visual impairment (VI), defined as a VA of 20/40 or worse in the better eye; blindness, defined as a VA of 20/200 or worse in the better eye; and doubling of the visual angle were measured.
Cumulative 14-year incidences of VI, doubling of the visual angle, and blindness were 12.7%, 14.2%, and 2.4%, respectively. In univariate analyses, loss of vision as measured by doubling of the visual angle is associated with older age, longer duration of diabetes, higher glycosylated hemoglobin, higher systolic and diastolic blood pressure, presence of proteinuria, more pack-years smoked, presence of macular edema, and more severe retinopathy. In logistic regression analyses, incidence of doubling of the visual angle is associated independently with retinopathy (odds ratio [OR], 1.07; 95% confidence interval [CI], 1.03, 1.11 for each level), glycosylated hemoglobin (OR, 1.46; 95% CI, 1.28, 1.66 for each 1%), proteinuria (OR, 2.32; 95% CI, 1.39, 3.88 for presence), and age (OR, 1.45; 95% CI, 1.20, 1.75 for 10 years). In addition, a change in glycosylated hemoglobin from baseline to the 4-year examination is associated with loss of vision (OR, 1.15; 95% CI, 1.02, 1.30 for a 1% increase).
Loss of vision continues to be significant in persons with diabetes. These results suggest that prevention of retinopathy through control of glycemia will have a beneficial effect on visual outcome.
本研究旨在评估糖尿病患者14年视力丧失的发生率,并探讨其与潜在危险因素的关系。
队列研究。
以人群为基础,选取年龄小于30岁且正在接受胰岛素治疗的年轻起病糖尿病患者样本(n = 880),在基线、4年、10年和14年时进行检查。
按照糖尿病视网膜病变早期治疗研究方案测量视力(VA)。
视力损害(VI),定义为较好眼的视力为20/40或更差;失明,定义为较好眼的视力为20/200或更差;以及视角加倍情况。
14年VI、视角加倍和失明的累积发生率分别为12.7%、14.2%和2.4%。在单因素分析中,以视角加倍衡量的视力丧失与年龄较大、糖尿病病程较长、糖化血红蛋白水平较高、收缩压和舒张压较高、蛋白尿的存在、吸烟包年数较多、黄斑水肿的存在以及视网膜病变更严重有关。在逻辑回归分析中,视角加倍的发生率独立与视网膜病变(比值比[OR],1.07;95%置信区间[CI],每增加一个级别为1.03,1.11)、糖化血红蛋白(OR,1.46;95%CI,每增加1%为1.28,1.66)、蛋白尿(OR,2.32;95%CI,存在时为1.39,3.88)和年龄(OR,1.45;95%CI,每增加10岁为1.20,1.75)相关。此外,从基线到4年检查时糖化血红蛋白的变化与视力丧失相关(OR,1.15;95%CI,每增加1%为1.02,1.30)。
糖尿病患者的视力丧失仍然很严重。这些结果表明,通过控制血糖来预防视网膜病变将对视力结局产生有益影响。